NGM Bio to Participate in Upcoming Investor Conferences
NGM Biopharmaceuticals (NGM) announced a presentation by CEO David J. Woodhouse, Ph.D., at two upcoming investor conferences. The B. Riley Virtual Annual Oncology Investor Conference will take place on January 27, 2022, at 2:30 PM ET, followed by the SVB Leerink’s 11th Annual Global Healthcare Conference on February 18, 2022, at 1:40 PM ET. Live webcasts will be accessible via NGM's website, with replay available for 30 days post-event. NGM focuses on developing transformative therapeutics for cancer, retinal diseases, and liver/metabolic diseases.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming virtual investor conferences.
B. Riley Virtual Annual Oncology Investor Conference
Thursday, January 27, 2022, 2:30pm ET
SVB Leerink’s Virtual 11th Annual Global Healthcare Conference
Friday, February 18th, 2022, 1:40pm ET
Live webcasts of presentations will be available under the Investors and Media section of NGM Bio’s website at https://ir.ngmbio.com/events-presentations. A replay of each presentation will be archived on NGM Bio’s site for at least 30 days following the event.
About NGM Biopharmaceuticals, Inc.
NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, with a disease-agnostic mindset, always led by biology and motivated by unmet patient need. Today, the company has seven disclosed programs, including four in Phase 2 or 2b studies, across three therapeutic areas: cancer, retinal diseases and liver and metabolic diseases. Visit us at www.ngmbio.com for more information.
| Investor Contact: Brian Schoelkopf ir@ngmbio.com | Media Contact: media@ngmbio.com |
FAQ
What events will NGM discuss in January 2022?
Who will present for NGM at the conferences?
How can I watch NGM's conference presentations?
What is NGM's focus in biopharmaceuticals?
How many programs does NGM have in development?
